Boston Scientific Corporation

Insights Into Boston Scientific (BSX) Q3: Wall Street Projections for Key Metrics

Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.

Boston Scientific Corporation $BSX Stock Bought by Integrated Advisors Network LLC

Boston Scientific: A Q3 Earnings Miss Likely Amid Product Recall, Cybersecurity Incident

Boston Scientific remains a 'hold' as growth decelerates and competitive pressures intensify, particularly in Watchman and electrophysiology segments. Management has shifted the growth focus to Interventional Cardiology, Endoscopy, and Neuromodulation, but meaningful improvements are not expected until 2028. Recent product recalls, a cybersecurity incident, and repeated guidance cuts further cloud near-term visibility and risk further downward revisions.

BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT:  Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation's Directors and Officers for Breach of Fiduciary Duties -- BSX

Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE: BSX) f

BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT:  Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation's Directors and Officers for Breach of Fiduciary Duties – BSX

NEW YORK--(BUSINESS WIRE)---- $BSX #NYSE--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE: BSX) failed to manage Boston Scientific in an acceptable manner, breaching their fiduciary duties to Boston Scientific, and whether Boston Scientific and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On February 4, 2026, B.

Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors

Boston Scientific (BSX) closed at $44.51 in the latest trading session, marking a -2.35% move from the prior day.

Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BSX Set to Report Q3 Earnings: Will MedSurg Strength Aid Performance?

Boston Scientific's Q3 results hinge on MedSurg strength in Endoscopy and Neuromodulation, as Cardiovascular faces competitive pressures and softer sales.